They raised data center growth from 35% to 60% in one quarter while holding capex at 4-5% of revenue. The China question went unanswered.
Thesis: A 1.5 book-to-bill with record backlog covers the next 12 months with non-cancellable orders. Data center guidance raised 20+ points reflects a real 1.6T ramp, not narrative. The asymmetry favors longs for 2-3 quarters because the constraint is demand, not supply. The capacity ceiling at 4-5% capex is a real 12-24 month problem, but it hasn't hit yet, and management is expanding within existing fabs at high utilization. The China concentration is an unquantifiable tail risk that Daly refused to address.
Verdict: LONG — Conviction: MEDIUM
Catalyst: Fiscal Q3 guide of $331-339M with data center at ~35% sequential growth and operating margin at 30% would confirm the raise and validate the leverage thesis.
Key Risk: Capacity ceiling: 4-5% capex ($55-65M) against 30%+ revenue growth. North Carolina 30% wafer capacity increase finishes end of calendar 2026. Management explicitly rules out greenfielding. If demand exceeds this constrained supply, they lose orders they already booked.
The Tell: Analyst Tim Savageaux asked directly about 'your very big customer in China who's doing extremely well' and its contribution to data center growth. Daly rewrote the question: 'Right. I think embedded in that question is really what's your exposure to the hyperscalers?' He then pivoted to platform diversity and 1.6T, never once mentioning China or quantifying the concentration. A direct question about a single-customer risk on 60% growth got zero response.
Friction Level: MODERATE_FRICTION — Both sides agree the numbers are exceptional. The disagreement is whether 4-5% capex against 30%+ growth creates a capacity ceiling within four quarters, and whether undisclosed China concentration can derail the data center guide.
2026Q2 · May 7, 2026
4 of 5 readings agreed4 LONG · 1 HOLDRead the full call
Book-to-Bill 1.5, Capacity Capex Still at 5%
A 1.5 book-to-bill with record backlog covers the next 12 months with non-cancellable orders. Data center guidance raised 20+ points reflects a real 1.6T ramp, not narrative. The asymmetry favors longs for 2-3 quarters because the constraint is demand, not supply. The capacity ceiling at 4-5% capex is a real 12-24 month problem, but it hasn't hit yet, and management is expanding within existing fabs at high utilization. The China concentration is an unquantifiable tail risk that Daly refused to address.
Analyst Tim Savageaux asked directly about 'your very big customer in China who's doing extremely well' and its contribution to data center growth. Daly rewrote the question: 'Right. I think embedded in that question is really what's your exposure to the hyperscalers?' He then pivoted to platform diversity and 1.6T, never once mentioning China or quantifying the concentration. A direct question about a single-customer risk on 60% growth got zero response.
11 consecutive quarters of sequential EPS growth. Data center FY26 growth raised from 35-40% to 60%+ in a single quarter. Operating margin guided from 27.8% to 30%. Gross margin exit target moved from 59% to near 60%. Every metric beat and every guide moved up.
Book-to-bill of 1.5 with largest quarterly bookings in company history, all within 12-month recognition window. All three end markets posting exceptional bookings. Backlog at record level. This covers the second half of FY26.
Gross margin expanded 90bps to 58.5% on fab utilization gains in Lowell and North Carolina. Operating margin hit 27.8%, third consecutive quarter of expansion, guided to 30%. OCF tracking to $300M+ on $55-65M capex. Cash generation is real and ahead of consensus.
GBP 45M IQE investment (GBP 30M equity for 11%, GBP 15M convertible) securing long-term indium phosphide and silicon carbide substrate supply. Backstop capacity expansion in North Carolina ($15-16M), Massachusetts GaN equipment, France MOCVD reactor, 3-inch to 6-inch conversion.
CapEx guidance of $55-65M at 4-5% of revenue against 30%+ growth trajectory. Management explicitly rules out greenfielding. North Carolina 30% capacity increase uses discounted equipment and finishes end of calendar 2026. At 30%+ growth, headroom consumed fast.
Management confirms orders spread over multiple quarters, only recognized within 12 months, but provides no cancellation terms or customer mix detail. Daly says 'we believe' rather than confirming contractual commitment.
CW laser process of record incomplete, management says model zero contribution for FY26 and FY27. CPO labeled 'TBD'. Revenue rests on legacy DFB and 1.6T PAM4 while customer roadmaps move toward CW lasers and silicon photonics.
Data center growth trajectory of 35% then 48% then 60%+ with no consumer backstop, entirely hyperscaler CapEx dependent. Large China customer flagged by analyst and never addressed by management.
+20
NEUTRAL"Direct, specific numbers on capacity ($15-16M NC fab, GBP 45M IQE) and margin trajectory. But hedges on forward catalysts: CW laser 'oftentimes it doesn't [work]', 60% margin exit 'we're not sure if that's gonna happen'. China question deflected entirely."
Rich financial detail: exact book-to-bill, segment revenue, DSO, inventory turns, cash flow, capex. Management gave specifics on capacity investments. But zero visibility on China customer mix, backlog cancellation terms, and optical device revenue breakdown.
Fiscal Q3 guide of $331-339M with data center at ~35% sequential growth and operating margin at 30% would confirm the raise and validate the leverage thesis.
Capacity ceiling: 4-5% capex ($55-65M) against 30%+ revenue growth. North Carolina 30% wafer capacity increase finishes end of calendar 2026. Management explicitly rules out greenfielding. If demand exceeds this constrained supply, they lose orders they already booked.
“MACOM Technology Solutions Holdings, Inc. expects revenue in fiscal Q2 ending April 3, 2026, to be in the range of $281 to $289 million.”
“Fiscal Q2 revenue was $289 million, up 6.4% sequentially and up over 22% year-on-year, driven by growth across all three of our end markets, with data center leading, followed by I&D and telecom.”
Companies tend to guide low: the median company we cover reports +1.7% against its guidance midpoint, so a small beat is the norm. A transcript can drop part of a guided range, so read both quotes.
“MACOM expects revenue in fiscal Q3, ending July 3rd, 2026 to be in the range of $331 million-$339 million.”
Changed less than 76% of calls
Wording compared with the Feb 5, 2026 call, ranked among 97 calls reporting on Q1 2026. A measure of how much the story moved, not a signal about the stock.
Figures are extracted from the transcripts and checked in code: every quote appears word for word. Language change is computed from word frequencies, with no model involved. Descriptive only: none of this feeds the verdict.
Book-to-bill 1.5 with largest bookings in company history, all non-cancellable within 12 months. Data center raised from 35-40% to 60%+ growth in one quarter. Operating margin at 27.8% heading to 30%. Eleven straight quarters of sequential EPS growth. OCF tracking to $300M+ on only $55-65M capex with net cash $325M. The 1.6T ramp through calendar 2026 is the structural driver and MACOM was early to it. Defense at 20%+ growth with US and European customers both accelerating. Lowell and North Carolina fabs improving utilization simultaneously. IQE GBP 45M secures substrate supply before it becomes a bottleneck. Competitor exit from RF power GaN is a real tailwind starting in 2027. The Street is behind on both the growth re-rate and margin trajectory.
China customer concentration flagged directly by an analyst and never addressed. CW laser has no process of record, management says model zero for FY26 and FY27. CPO is 'TBD'. Revenue rests on legacy DFB and 1.6T while customer roadmaps move to CW lasers and silicon photonics. Capacity ceiling is structural: 4-5% capex against 30%+ growth, no greenfielding allowed, NC 30% capacity increase finishes end of calendar 2026. Backlog spread over quarters with no cancellation terms disclosed. LEO ramp explicitly deferred to calendar 2027. Adjusted EPS benefits from 3% tax rate on $202M deferred tax assets. IQE investment is defensive substrate risk management, not strength. The 60% margin exit is qualified: 'we're not sure if that's gonna happen.'
China Revenue Decline Masked
Analyst named 'your very big customer in China' contributing to data center growth. Daly pivoted to hyperscaler exposure without addressing China. Export control expansion against Chinese module makers would hit 60% growth guide directly with no replacement market on that timescale.
Capacity Ceiling
Capex held at 4-5% of revenue ($55-65M) against 30%+ growth. NC 30% capacity increase done end of calendar 2026. Management explicitly rules out greenfielding. At this growth rate, capacity headroom is consumed within 2-3 quarters.
Generation-Skipping Execution Risk
CW laser process of record incomplete, contribution pushed to FY27-28. CPO labeled TBD. Revenue depends on legacy DFB while market architecture shifts to CW lasers and silicon photonics. Two architectural transitions with zero current revenue.
Backlog Quality
1.5 book-to-bill is within 12-month recognition but spread over multiple quarters. No cancellation terms, no customer mix detail. Management says 'we believe' rather than stating contractual fact.
Mix Shift Spin
Legacy DFB laser demand framed as share gain opportunity while competitors pivot to CW lasers for silicon photonics. Management positions gap-filling as strategy rather than interim revenue.
LONG, medium conviction, sized for 2-3 quarter hold. The asymmetry favors longs on the near-term: 1.5 book-to-bill covers FY26, guidance raised 20+ points, operating leverage confirmed at 30% margin. Data center 35% sequential guide for Q3 is concrete. The capacity ceiling and China concentration are real 12-24 month risks, not now risks. Trim into strength if data center sequential growth decelerates below 20% or if China export controls tighten against Chinese module makers. Stop out if book-to-bill drops below 1.1.